C ardiac arrest remains common in the United States, and nearly 600,000 people suffer sudden cardiac death in Europe and the United States yearly. Survival, however, has remained low, estimated to be 5%-12% (1, 2) . In part, the poor survival is due to the inefficiency of standard cardiopulmonary resuscitation (CPR), resulting in Ͻ25% of normal blood flow to the brain and heart (3).
In an effort to optimize the thoracic pump mechanics and augment forward and vital organ blood flow during resuscitation by harnessing the elastic properties of the chest during decompression, the inspiratory impedance threshold device (ITD) was introduced to the world of resuscitation about 20 yrs ago. The inspiratory ITD is attached to the airway either via a facemask or an endotracheal tube. The ITD impedes air entry into the chest cavity during the decompression phase of CPR, generating more negative intrathoracic pressure than standard CPR. This vacuum has been demonstrated to improve venous return to the heart as well as reduce intracranial pressure (4). In a porcine model of cardiac arrest, the use of an ITD led to improved 24-hr survival with improved neurologic outcomes (5-7). As a result of favorable hemodynamic, survival, and neurologic outcomes in animal studies, there have been several clinical trials that investigated the ITD in animals and humans (8 -10). The ITD has been cleared by the Food and Drug Administration as a cir-culatory enhancer during resuscitation. Most of the animal and clinical studies have shown benefits in different end points. The ITD has been shown to improve aortic pressure during CPR (11), and increase resuscitation rates in humans and hospital admission rates when it was applied appropriately and during the early phases of cardiac arrest; namely the circulatory phase (4 -10 mins of untreated cardiac arrest) (12). In a recent study, the ITD demonstrated no benefit compared to a sham valve in 10,000 patients (8). While this was the largest clinical trial in CPR to date, it was confounded by the fact that the ITD was placed, on average, 11-14 mins after the 911 call, well into the metabolic phase of cardiac arrest where it is very unlikely that any circulation-enhancing device could demonstrate benefits.
The concept of intrathoracic pressure regulation and its efficacy in clinical practice has been shown broadly in five clinical studies where active compression-decompression CPR has been combined with the ITD. The combination is hemodynamically superior and has resulted in improvement in all the end points of resuscitation science. A recent study showed that active compressiondecompression CPRϩITD (and for the first time for a new CPR method) significantly increased survival to hospital discharge, with favorable neurologic outcomes (defined as modified Rankin score Ͻ3), by 50% when compared with standard CPR (6% vs. 9%, p ϭ .019) (9). The benefits were maintained up to 1-yr survival, which was also improved by 53%.
In this issue of Critical Care Medicine, Pantazopoulos and colleagues (13) tested the addition of an ITD in a porcine model of asphyxial cardiac arrest. This is an important study. As the authors correctly point out, it is the first investigation of the use of the ITD in asphyxial cardiac arrest. The study is very innovative since inspiratory impedance during resuscitation of asphyxial cardiac arrest appears to be counterintuitive. The authors provide evidence of improvement in clinically relevant end points, such as return of spontaneous circulation, 48-hr survival, and neurologic alertness score. In addition to the improved neurologic outcomes, the measurement of early serum neuronspecific enolase and S-100 levels provides additional evidence of decreased neurologic insult during resuscitation. As such, their results are intriguing and very supportive of the literature of cardiac etiology cardiac arrest, and therefore expand the benefits of the ITD into another etiology (14).
The potential mechanism of how the ITD may be neuroprotective and improve outcomes compared to standard CPR in this model may be due to direct transfer of intrathoracic pressure into intracranial pressure. A lower intrathoracic pressure therefore is translated into lower diastolic intracranial pressure.
The lower intracranial pressure combined with the higher aortic pressure leads to more cerebral perfusion and blood flow that could alleviate the injury during the resuscitation, even after asphyxia, provided that ventilation and oxygenation has been reestablished.
One limitation of the current study by Pantazopoulos et al is that epinephrine was not used. Epinephrine is routinely used in human resuscitation and enhances successful return of spontaneous circulation (15), but has been shown to reduce neurologically intact survival in high doses. The beneficial effects of the ITD may be mitigated by the use of vasopressors, often required in substrates less healthy than in this animal model, however, previous animal studies have demonstrated mixed outcomes in this respect. Further translation of this model is limited due to its low prevalence, however, it adds to the substantial body of animal studies and growing number of clinical trials investigating the use of intrathoracic pressure regulation therapy, such as the ITD.
In conclusion, although the results of animal studies must be scrutinized carefully regarding their translation into clin-ical medicine, the results presented by Pantazopoulos et al can be combined with the observations from clinical and animal investigations to date. The data suggest that when an ITD is applied in a timely fashion, before the metabolic phase of cardiac arrest, it provides not only favorable hemodynamics during CPR, but also improves return of spontaneous circulation rates and survival with good neurologic outcomes even in an a model of asphyxia.
Jason Atelectrauma: Mechanistic insights tempered by clinical relevance?* T he mechanisms involved in ventilator-induced stress injury to the cells and tissues of the lung remain contentious with direct investigation limited to the difficult, costly, and restrictive technique of electron microscopy, which has provided clear evidence of damage, including that of plasma membrane breaks (1). However, the development of models that allow "real-time" monitoring of not only plasma membrane injury during injurious ventilation, but also subsequent repair has facilitated a substantial step forward in our understanding of ventilator-induced lung injury (VILI) at the cellular level. Initial studies (2) used ex vivo lung preparations in which the DNA interchelating agent propidium iodide was used as a fluorescent marker for cells with plasma membrane breaks. Vlahakis and coworkers (3) used this model to elegantly demonstrate the trafficking of lipid from intracellular reservoirs for the prevention of plasma membrane breaks and, with the addition of a secondary intra-alveolar fluorescent marker, the repair of plasma membrane breaks (4). These findings suggest not only a reconsideration of irreversible injury resulting from mechanical stress, but also the complex relationship between stress and the production of mediators associated with both local inflammation and with multiple organ dysfunction (5-7). However, the ex vivo nature of these techniques prevented investigation of the interaction with the systemic circu-lation as well as the nervous and endocrine systems.
In this issue of Critical Care Medicine, Pecchiari and coworkers (8) present an alternate model for the quantification and distribution of plasma membrane breaks throughout the in vivo lung. Using a similar DNA chelating technique, Pecchiari intratracheally instilled a double-labeling mixture capable of identifying plasma membrane breaks and indicating cell viability after potentially injurious vs. noninjurious ventilation. Adding to their previous work describing discontinuity between VILI at low lung volumes and inflammatory cytokine production (9), they report distinct differences in the density, distribution, and repair of plasma membrane disruptions in the lung dependant on the mechanism of VILI. Although high tidal volume results in VILI with leukocyte infiltration, inflammatory cytokine production, and plasma membrane disruption in both the
